Lisa Delfini - Trevi Therapeutics Chief Officer
| TRVI Stock | USD 2.88 0.04 1.37% |
Insider
Lisa Delfini is Chief Officer of Trevi Therapeutics
| Age | 54 |
| Address | 195 Church Street, New Haven, CT, United States, 06510 |
| Phone | 203 304 2499 |
| Web | https://www.trevitherapeutics.com |
Latest Insider Transactions
Lisa Delfini Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lisa Delfini against Trevi Therapeutics stock is an integral part of due diligence when investing in Trevi Therapeutics. Lisa Delfini insider activity provides valuable insight into whether Trevi Therapeutics is net buyers or sellers over its current business cycle. Note, Trevi Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Trevi Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lisa Delfini over six months ago Disposition of 2291 shares by Lisa Delfini of Trevi Therapeutics at 0.511 subject to Rule 16b-3 | ||
Lisa Delfini over six months ago Acquisition by Lisa Delfini of 2291 shares of Trevi Therapeutics at 0.511 subject to Rule 16b-3 | ||
Lisa Delfini over six months ago Acquisition by Lisa Delfini of 175000 shares of Trevi Therapeutics at 2.38 subject to Rule 16b-3 |
Trevi Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3657) % which means that it has lost $0.3657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5965) %, meaning that it created substantial loss on money invested by shareholders. Trevi Therapeutics' management efficiency ratios could be used to measure how well Trevi Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.34. The current Return On Capital Employed is estimated to decrease to -0.43. As of now, Trevi Therapeutics' Non Currrent Assets Other are increasing as compared to previous years.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ming Yin | Bolt Biotherapeutics | N/A | |
| Fanny Cavalie | Foghorn Therapeutics | 46 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Scott Smith | Bioatla | 62 | |
| Steven Bellon | Foghorn Therapeutics | 59 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Laurent Chardonnet | Prelude Therapeutics | 59 | |
| MBA CFA | Bolt Biotherapeutics | 60 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| MD MBA | Rezolute | N/A | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Peggy Scherle | Prelude Therapeutics | 62 | |
| Michael LaCascia | Foghorn Therapeutics | 59 | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| Scott Thomas | Seer Inc | 51 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 |
Trevi Therapeutics Leadership Team
Elected by the shareholders, the Trevi Therapeutics' board of directors comprises two types of representatives: Trevi Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Trevi. The board's role is to monitor Trevi Therapeutics' management team and ensure that shareholders' interests are well served. Trevi Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Trevi Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Farrell PharmD, Chief Officer | ||
| James Cassella, Chief Director | ||
| Christopher Galletta, Controller Officer | ||
| AFPM MD, Chief Officer | ||
| Danine Summers, Vice Affairs | ||
| Lisa Delfini, Chief Officer | ||
| Jennifer Good, CEO, CoFounder | ||
| Thomas MD, CoFounder Officer | ||
| Katie McManus, Communications Manager |
Trevi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Trevi Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 159.3 M | ||||
| Shares Outstanding | 76.87 M | ||||
| Shares Owned By Insiders | 1.18 % | ||||
| Shares Owned By Institutions | 80.60 % | ||||
| Number Of Shares Shorted | 1.72 M | ||||
| Price To Book | 3.79 X | ||||
| EBITDA | (33.8 M) | ||||
| Net Income | (29.07 M) |
Currently Active Assets on Macroaxis
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Return On Assets (0.37) | Return On Equity (0.60) |
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.